Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21673566 | 1.00 | ADRB2 (0.38) | ADRB2ADRB1ADRB3KDM4EMTNR1A | |
| SCHEMBL18551629 | 0.85 | SLC6A4 (0.35) | MTNR1AMTNR1B | |
| SCHEMBL18551612 | 0.85 | SLC6A4 (0.35) | MTNR1AMTNR1B | |
| SCHEMBL22297545 | 0.84 | ALDH1A1 (0.33) | MTNR1AMTNR1B | |
| SCHEMBL21771300 | 0.84 | ALDH1A1 (0.33) | MTNR1AMTNR1B | |
| SCHEMBL18592295 | 0.83 | ADRB2 (0.36) | ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL18592298 | 0.83 | ADRB2 (0.36) | ADRB2ADRB1ADRB3KDM4E | |
| SCHEMBL21025855 | 0.81 | ADRB2 (0.35) | ADRB2ADRB1ADRB3 | |
| SCHEMBL20133408 | 0.81 | ADRB2 (0.35) | ADRB2ADRB1ADRB3 | |
| SCHEMBL26853183 | 0.81 | GCK (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2018119441-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | ADRB2 3638/4885ADRB1 3699/4885ADRB3 3981/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | ADRB2 3638/4885ADRB1 3699/4885ADRB3 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.